Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

ADARx Pharmaceuticals, Inc.

ADRX · Nasdaq · CIK 0001802369 · Healthcare · Biotechnology

INSIDER SIGNAL

90.6 / 100

5 buyers · 11 purchase transaction lines · $67.6M gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeStrong
RoleModerate
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+35.0 / 35
Purchase size+24.4 / 25
Role+14.0 / 20
Recency+7.2 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Role scores low · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
  • ✓ Cluster breadth is broad · 4+ insiders
  • ✓ Recent activity · latest purchase 2026-09-28

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Chimovits ErezDirector
○●
GORDON CARL LDirector,TenPercentOwner
○●
ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.Director,TenPercentOwner
○●
SR ONE CAPITAL MANAGEMENT, LLCTenPercentOwner
○●
George SimeonDirector,TenPercentOwner
○●
LAV Biosciences Fund V, L.P.; LAV Fund VI Opportunities, L.P.; LAV Fund VI, L.P.TenPercentOwner
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS5
PURCHASE CONCENTRATION25%Largest buyer: SR ONE CAPITAL MANAGEMENT, LLC · $17.1M
CLUSTER BUYING · 15D5 insidersPeak activity: 2026-09-28–2026-09-28

Roles in the peak window: Director, Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

90.6 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 91.2
  2. 91.1
  3. 91.0
  4. 90.8
  5. 90.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

11Purchases
0Sales
37Other Form 4 lines
6SEC filings · 365 days
BUYING11 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER37 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDUnavailable

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
—
3M
—
6M
—
12M
—

Volatility & liquidity

Volatility
—
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,163,375
Previous report
0
Avg daily volume
669,771
Days to cover
1.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.Purchase (P)Common Stock950,000USD 17.00USD 16,150,000SEC filing ↗
2026-09-28GORDON CARL LPurchase (P)Common Stock950,000USD 17.00USD 16,150,000SEC filing ↗
2026-09-28Chimovits ErezPurchase (P)Common Stock61,516USD 17.00USD 1,045,772SEC filing ↗
2026-09-28SR ONE CAPITAL MANAGEMENT, LLCPurchase (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC filing ↗
2026-09-28George SimeonPurchase (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC filing ↗

Form 4 evidence

48 transaction lines in the latest 365-day window; 48 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.Purchase (P)Common Stock950,000USD 17.00USD 16,150,000SEC filing ↗
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.C (C)Common Stock23,255,789USD —USD —SEC filing ↗
2026-09-28GORDON CARL LPurchase (P)Common Stock950,000USD 17.00USD 16,150,000SEC filing ↗
Show recent Form 4 evidence (11 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.Purchase (P)Common Stock950,000USD 17.00USD 16,150,000SEC filing ↗
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.C (C)Common Stock23,255,789USD —USD —SEC filing ↗
2026-09-28GORDON CARL LPurchase (P)Common Stock950,000USD 17.00USD 16,150,000SEC filing ↗
2026-09-28GORDON CARL LC (C)Common Stock23,255,789USD —USD —SEC filing ↗
2026-09-28Chimovits ErezPurchase (P)Common Stock61,516USD 17.00USD 1,045,772SEC filing ↗
2026-09-28Chimovits ErezC (C)Common Stock9,230,509USD —USD —SEC filing ↗
2026-09-28SR ONE CAPITAL MANAGEMENT, LLCPurchase (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC filing ↗
2026-09-28SR ONE CAPITAL MANAGEMENT, LLCC (C)Common Stock8,336,661USD —USD —SEC filing ↗
2026-09-28LAV Biosciences Fund V, L.P.; LAV Fund VI Opportunities, L.P.; LAV Fund VI, L.P.C (C)Common Stock11,550,917USD —USD —SEC filing ↗
2026-09-28George SimeonPurchase (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC filing ↗
2026-09-28George SimeonC (C)Common Stock8,336,661USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerADRX
CIK0001802369
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history48 transaction lines from 2026-09-28 to 2026-09-28
11 P purchase lines · 0 S sale lines · 37 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.